News

The product incorporates Circ Pharma’s drug delivery technology enabling once daily dosing. Circ’s technology provides for minimized delivery to the body during sleeping hours, acceleration of drug absorption

Australian pharmaceutical company Pharmaxis has reported positive results of its recently completed international Phase III trial of Bronchitol in people with cystic fibrosis. The primary endpoint of the

The patent, issued in Australia, covers Thymosin Beta 4, its analogues, isoforms and other derivatives and expires in 2022. Currently, RegeneRx is developing three product candidates, RGN-137, RGN-259

Biovail Laboratories International (BLS) has acquired the US and Canadian rights to develop, manufacture and commercialize pimavanserin tartrate in a number of neurological and psychiatric conditions, including Parkinson’s

Under the agreement, the two companies will develop diagnostic products that incorporate Fujirebio Diagnostics’s cancer biomarkers for use on Becton, Dickinson and Company’s (BD) multiplex testing platform. The

By means of this exclusive licensing-in agreement Almirall will be responsible for the commercialization of linaclotide in all country members of the EU, plus Russia, CIS, Switzerland, Norway

Christine Horton, CEO of CoreSpine Technologies, said: “The clearance of the Xtend-ST device is truly a significant achievement for CoreSpine. The Xtend-ST is a safe and effective device

The planned 46 patients have been enrolled and are currently undergoing treatment and follow-up. The primary objective of the multi-center, open-label Phase II study is to assess the

Under the terms of the agreement, Tessella and Cmed will ensure interoperability of Timaeus, the intelligent data acquisition and management system with Tessella Fates, Tessella’s fixed and adaptive